Toshihiro Maeda
Clinical Development Department, The Chemo-Sero-Therapeutic Research Institute (Kaketsuken),
1314-1 Kyokushikawabe, Kikuchi, Kumamoto 869-1298
Japan
Research Article
Characterization of the Recombinant Der F 2 Mutant C8/119S and Evaluation of C8/119S in a Rder F 2-Sensitized Rhinitis Mice Model
Author(s): Satoshi Koyanagi*, Toshio Murakami, Kazuyuki Nakashima, Toshihiro Maeda, Yoshinobu Miyatsu, Keishin Sugawara and Hiroshi MizokamiSatoshi Koyanagi*, Toshio Murakami, Kazuyuki Nakashima, Toshihiro Maeda, Yoshinobu Miyatsu, Keishin Sugawara and Hiroshi Mizokami
Immunotherapy is the only curative approach to treat allergy, but carries the risk of anaphylaxis. C8/119S is a mutant of Der f 2, which is one of the causative allergens of perennial allergic diseases, and has been selected to decrease the risk of anaphylaxis in immunotherapy. In this study, the physical properties of C8/119S were determined, and the efficacy of C8/119S was evaluated in a NC/Nga mouse rhinitis model. C8/119S and recombinant Der f 2 (rDer f 2) were expressed in Escherichia coli . Purified allergens were analyzed by physicochemical and immunological techniques. In addition, rhinitis was provoked in rDer f 2-sensitized NC/Nga mice by nasal administration of rDer f 2, and C8/119S was administered. After provocation tests with rDer f 2, the number of eosinophils infiltrating the nasal mucosa was determined. C8/119S had a disordered structure, and the binding activity of a.. View More»
DOI:
10.4172/2155-6121.1000105